Paradigm shift in NMDA receptor drug development
- 10 June 2005
- journal article
- Published by Informa Healthcare in Emerging Therapeutic Targets
- Vol. 9 (3), 427-429
- https://doi.org/10.1517/14728222.9.3.427
Abstract
Low-affinity, uncompetitive antagonists with rapid 'off-rates', such as memantine offer protection from dementia and other neurological disorders, but break all the old rules of screening for new drugs by high-affinity binding.Keywords
This publication has 5 references indexed in Scilit:
- Memantine in Moderate-to-Severe Alzheimer's DiseaseNew England Journal of Medicine, 2003
- Mechanism of memantine block of NMDA‐activated channels in rat retinal ganglion cells: uncompetitive antagonism.The Journal of Physiology, 1997
- Excitatory Amino Acids as a Final Common Pathway for Neurologic DisordersNew England Journal of Medicine, 1994
- Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxideTrends in Neurosciences, 1993
- Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicityJournal of Neuroscience, 1992